Gerresheimer Ag · XETR:GXI
Gerresheimer — Sal. Oppenheim European Healthcare Investors Conference 2008
15 slides from Gerresheimer's conference presentation, Sep 2, 2008
Slide 1: Gerresheimer – A Leading Partner for the Pharma & Life Science Industry
Gerresheimer – A Leading Partner for the Pharma & Life Science Industry Sal. Oppenheim European Healthcare Investors Conference Frankfurt, September 2, 2008 Hans-Jürgen Wiecha, CFO 0
Slide 2: Disclaimer
Disclaimer This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or
Slide 3: Investment summary: defensive growth stock
Investment summary: defensive growth stock Strong focus on Pharma & Life Science Industry with favorable growth drivers Leading market positions in attractive niche markets High barriers to entry due to regulatory environment Long-lasting relationships with blue-chip customers Very limited R&D expos
Slide 4: Gerresheimer at a glance
Gerresheimer at a glance Consolidated net sales FY 2007: EUR 957.7m Tubular Glass Plastic Systems Moulded Glass Life Science (Plastic Drug Delivery and (Injectable Glass and Systems) Systems) Research Net sales: EUR 271.2m Net sales: EUR 299.7m1 Net sales: EUR 318.8m EUR 72.2m Adj. EBITDA margin: 24
Slide 5: Gerresheimer is a global player
Gerresheimer is a global player Region Plants Employees Europe 21 5,876 The Americas 13 3,139 Asia 6 1,296 Total 40 10,311 As of May 31, 2008 Headquarters Tubular Glass Plastic Systems Moulded Glass Life Science Research 4
Slide 6: Highly attractive end market trends drive growth for Gerresheimer products
Highly attractive end market trends drive growth for Gerresheimer products Aging of world population Development of healthcare systems in emerging countries Growing number of acute and chronic diseases Accelerating pace in drug development Growth in biotech drugs and generics Outsourcing trend of Dr
Slide 7: Leading market positions in attractive niche markets
Leading market positions in attractive niche markets Tubular Glass Plastic Systems Life Moulded Division (Injectable Glass (Plastic Drug Delivery Science and Systems) and Systems) Glass Research Inha- Diabetes OTC Liquids Glass Other Plastic Product Tubing Syringes Injectables Packaging lation Diagn
Slide 8: Gerresheimer provides its Pharma & Life Science customers with solutions across all key product categories
Gerresheimer provides its Pharma & Life Science customers with solutions across all key product categories Tubular Glass Plastic Systems Life Science Division (Injectable Glass and (Plastic Drug Delivery and Moulded Glass Research Systems) Systems) Other Plastic Diabetes OTC liquids Glass Glass Phar
Slide 9: High barriers to entry support strong market positions
High barriers to entry support strong market positions Technological factors Start-up factors Regulatory environment (FDA & EMEA Proven track record is a prerequisite authorities, Pharmacopeia reference High investment requirements standards, GMP – Good Manufacturing Adoption of technological know-h
Slide 10: Well-diversified blue-chip customer base
Well-diversified blue-chip customer base Net sales to Top 50 customers (FY 2007) Pharma & Life Science Other EUR m Cumulative share in % 301 60% 56% 51% 43% 31% 114 73 50 38 Top 10 11-20 21-30 31-40 41-50 Gerresheimer has close long-term relationships …with limited dependence on individual with lead
Slide 11: Gerresheimer’s strategy
Gerresheimer’s strategy Targeted investments in growing segments Organic Continuous productivity and quality improvement growth Further capitalize on leading Pharma/ market positions life science Global market Extension of product leadership Growth offerings/technology positions through Extension of
Slide 12: Gerresheimer’s growth strategy is based on three pillars
Gerresheimer’s growth strategy is based on three pillars Acquisitions Growth Main areas: Above- projects -Primary Pharmaceutical market Packaging -Drug Delivery growth -Diagnostics rate Base growth New products/tech- -Medical Device Systems nologies at existing -Life Science Research Benefit from 6.
Slide 13: Business Outlook: Guidance FY 2008
Business Outlook: Guidance FY 2008 Growth rate of continuing business: 14-16% at constant FX rate Growth rate reflecting recent divestments: Net Sales 12.5-14.5% at constant FX rate Growth rate reflecting recent divestments and FX rate of EUR 1 = USD 1.55: 9-11% Mid 19% Adj. EBITDA margin Expected i
Slide 14: Financial Calendar 2008 / 2009
Financial Calendar 2008 / 2009 October 15, 2008 Interim Report 3rd Quarter 2008 October 23+24, 2008 Capital Markets Day 2008 February 17, 2009 Full Year Results 2008 April 29, 2009 Annual General Meeting 13
Slide 15: Investor Relations Contact Details
Investor Relations Contact Details Phone: +49 211 6181 – 257 Fax: +49 211 6181 – 121 E-mail: investorrelations@gerresheimer.com Please visit our IR website: www.gerresheimer.com/ir 14
Gerresheimer — Sal. Oppenheim European Healthcare Investors Conference 2008 on 6ix